-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on AbbVie, Lowers Price Target to $230

Benzinga·02/05/2026 15:27:40
Listen to the news
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $230.